Method for concentrating regeneration factor in blood by using aqueous two-phase system
The method employing ATPS with sodium sulfate, PEG, and hyaluronic acid effectively concentrates regenerative factors in blood, overcoming previous challenges by achieving high yields and purification, facilitating tissue regeneration and wound healing with antioxidant benefits.
Patent Information
- Application Number
- PCT/KR2024/006894
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for concentrating regenerative factors in blood, such as aqueous solution bisection, face challenges in achieving high yields and purification due to non-specific separation mechanisms and the need for careful balance of operating parameters, making it difficult to obtain desired target materials efficiently.
A method using aqueous two-phase systems (ATPS) to extract and concentrate regenerative factors by creating two aqueous phases, specifically employing sodium sulfate, PEG, and hyaluronic acid, along with centrifugation and chromatography, to produce regeneration factor-rich plasma (RRP) with enhanced concentration and purification.
The method achieves a high yield of regenerative factors, concentrating them up to 5 times more than whole blood, enabling effective tissue regeneration and wound healing, and demonstrating antioxidant effects on human skin cells.
Smart Images

Figure KR2024006894_28112024_PF_FP_ABST
Abstract
Description
Method for concentrating regenerative factors in blood using an aqueous two-phase system
[0001] The present invention relates to personalized healthcare and innovative new drugs, and more particularly, to a method for producing regeneration factor-rich plasma (RRP) by extracting and concentrating regeneration factors in blood using aqueous solution fractionation, and a method for applying the same to cosmetics and wound treatment.
[0002]
[0003] Regeneration factors, also called growth factors, are proteins involved in cell growth, proliferation, and differentiation and are known to include various types, including bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
[0004] Aqueous fractionation is a method of concentrating and extracting particles by creating two aqueous phases. It is formed when two polymers (one polymer and one kosmotropic salt) or two salts (one chaotropic salt and the other kosmotropic salt) are mixed at appropriate concentrations or at a specific temperature. Aqueous fractionation is composed mostly of water and non-volatile components, and has been used for many years in biotechnology applications as a non-denaturing and amphoteric separation medium to remove volatile organic compounds. However, the type and concentration of the substances forming the aqueous fraction are very important for the effective concentration and extraction of target substances. However, a method for concentrating and extracting only regeneration factor-rich plasma (RRP) using aqueous fractionation has not yet been developed. However, despite the above difficulties, the present invention has completed the invention by developing a method for producing RRP (Regeneration Factor-rich Plasma) containing five times more regeneration factors and proteins than whole blood using an aqueous solution dichotomous method.
[0005]
[0006] One object of the present invention is to provide a method for extracting or concentrating regeneration factor-rich plasma (RRP) from blood using aqueous solution fractionation.
[0007] Another object of the present invention is to provide a skin care method, a skin care cosmetic or a skin care composition comprising RRP extracted or concentrated through the above method.
[0008] Another object of the present invention is to provide a composition for treating a wound or a composition for treating a bone disease comprising RRP extracted or concentrated through the above method.
[0009] Another object of the present invention is to provide a device for extracting or concentrating RRP (Regeneration factor-rich plasma) from blood using an aqueous solution fractionation method, the device comprising: a rubber stopper (10); a lid (20) positioned below the rubber stopper; a main body (30) connected to the lid to perform centrifugation to separate RRP; a rubber stopper (40) positioned below the main body (30); and a support (50) connected to the main body (30) and the rubber stopper (40) and positioned below the main body.
[0010]
[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0012]
[0013] Various embodiments of the present invention are described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and processes, are set forth to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and configurations. In other instances, well-known processes and manufacturing techniques are not described in specific detail so as not to unnecessarily obscure the present invention. Reference throughout this specification to an embodiment means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the appearance of an embodiment in various places throughout this specification does not necessarily indicate the same embodiment of the present invention. Additionally, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
[0014]
[0015] To achieve the above purpose,
[0016] The present invention provides a method for producing a regeneration factor-rich plasma (RRP) material, comprising the steps of: (a) extracting plasma from extracted whole blood; (b) removing platelets and exosomes from the plasma; (c) extracting and concentrating regeneration factor-rich plasma (RRP) from the plasma using an aqueous solution fractionation method; (d) purifying impurities from the RRP; and (e) selectively extracting regeneration factors from the RRP.
[0017] In another embodiment of the present invention, the concentration step (b) is performed by removing exosomes using centrifugation and chromatography. Platelets are removed by using a centrifuge at 100 g force for 10 minutes, and then an ultracentrifuge at 10,000 g force for 2 hours is used, after which exosomes are removed using an agarose gel chromatography method.
[0018]
[0019] In another embodiment of the present invention, the concentration step (c) extracts and concentrates RRP (Regeneration factor-rich Plasma) using 4.3% sodium sulfate, 16% PEG (molecular weight 8000), and 3% hyaluronic acid. In yet another embodiment of the present invention, the concentration of sodium sulfate may be 1.0 to 10.0 wt %, 1.2 to 5.3 wt %, 2.5 to 5.3 wt %, 3.0 to 5.0 wt %, 3.5 to 5.0 wt %, 3.0 to 9.0 wt %, 3.0 to 8.5 wt %, 3.0 to 8.0 wt %, or 3.5 to 8.0 wt %.
[0020] In another embodiment of the present invention, the concentration of PEG may be 5 to 20 wt %, or 7 to 20 wt %, 8 to 20 wt %, 9 to 20 wt %, 10 to 20 wt %, or 10 to 18 wt %.
[0021] In another embodiment of the present invention, hyaluronic acid may be present in an amount of 1 to 10 wt %, 1 to 8 wt %, 1 to 7 wt %, 1 to 6 wt %, 2 to 6 wt %, 2 to 7 wt %, or 1 to 9 wt %.
[0022]
[0023] In another embodiment of the present invention, the average molecular weight of hyaluronic acid may be 100,000 or more and 500,000 or less.
[0024] In some cases, hyaluronic acid can be replaced with other additives, and applicable additives include (NH4)2SO4, Na2SO4, MgSO4, K2HPO4, KH2PO4, NaCl, KCl, NaBr, NaI, LiCl, n-Bu4NBr, n-Pr4NBr, Et4NBr, Mg(OH)2, Ca(OH)2, Na2CO3, ZnCO3, Ca3(PO4)2, ZnCl2, (C2H3)2Zn, ZnCO3, CdCl2, HgCl2, CoCl2, (CaNO3)2, BaCl2, MgCl2, PbCl2, AlCl3, FeCl2, FeCl3, NiCl2, AgCl, AuCl3, CuCl2, sodium dodecyl sulfate, sodium tetradecyl sulfate, There are dodecyltrimethylammonium bromide, dodecyltrmethylammonium chloride, and tetradecyltrimethylammonium bromide.
[0025] Additionally, usable additives may be one hydrophilic polymer selected from the group consisting of polyarginine, polylysine, polyethylene glycol, polypropylene glycol, polyethylene imine, chitosan, protamine, polyvinylacetate, hyaluronic acid, chondroitin sulfate, heparin, alginate, hydroxyoxypropyl methylcellulose, gelatin, starch, poly(vinyl methyl ether ether), polyvinylpyrrolidone, and combinations thereof.
[0026] Additionally, it may be one hydrophilic polymer selected from the group consisting of cyclodextrin, glucose, dextran, mannose, sucrose, trehalose, maltose, ficoll, inositol, mannitol, sorbitol, sucrose-mannitol, glucose-mannitol, trehalose-polyethylene glycol, sucrose-polyethylene glycol, sucrose-dextran, and combinations thereof.
[0027]
[0028] In another embodiment of the present invention, the purification step (d) removes HDL and LDL using a chromatography filter immobilized with Apo A and Apo B antibodies, and at this time, the pore size of the filter is preferably 1 um or more and 10 um or less.
[0029]
[0030] In another embodiment of the present invention, the selective extraction step (e) preferably comprises attaching the selected protein to a chromatography filter on which an anti-regenerative factor antibody is immobilized, and then recovering the selected protein from the filter using a preservation buffer. Available antibodies include, but are not limited to, antibodies against bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
[0031]
[0032] The present invention also includes a device capable of performing the method of the present invention, and provides (g) a step of extracting and concentrating RRP from plasma.
[0033]
[0034] (g) Equipment capable of performing the step of extracting and concentrating RRP from plasma can be implemented in two types. The first type is manufactured using an automated pipette, and the second type is implemented in a centrifugation container that can easily extract the concentrated RRP with a syringe after centrifuging whole blood.
[0035]
[0036] The present invention is described below.
[0037] While there have been cases of therapeutic applications utilizing platelet concentrates in plasma, the heterogeneous nature of platelets in blood has made approval for these treatments challenging. To date, these treatments have only been approved for use in medical procedures. Stem cell therapies and stem cell-derived exosome therapies also face challenges in gaining approval as therapeutic agents due to their heterogeneous nature.
[0038] This patent proposes a method and device for extracting bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF) with high efficiency and purity by concentrating RRP in blood. There have been no cases of therapeutic materials being developed using this method.
[0039]
[0040] 또한 기존 RRP를 적용할 수 있는 병증이나 시술로는 Temporomandibular Disorders, Gastric Ulcer Caused by Endoscopic Submucosal Dissection, Human Autologous Fat Transfer, the Treatment of Knee Osteoarthritis, the Treatment of Chronic Non-Healing Ulcers, Hair Restoration Therapy for Androgenetic Alopecia, Treatment for ACHILLES Tendon Tears, High Risk Proliferative Diabetic Retinopathy, High Risk Proliferative Diabetic Retinopathy, Knee OA, Patella-Dislocation, Lumbar Facet Joint Syndrome, Retinitis Pigmentosa, Diabetic Macular Edema, Traumatic Bone Cyst, High Risk Proliferative Diabetic Retinopathy, Scar, Dry Eye, Sjogren Syndrome, Osteoarthritis, Meniscus Lesion, Melasma, Muscle Injury, Ulnar Neuropathy at Elbow, Chronic Ulcer, Alopecia, Epicondylitis, Bone Resorption, Rotator Cuff Tears, Thin Endometrium, Striae Gravidarum, Plantar Fascitis, Coxarthrosis, Osteoarthritis, Muscle Tear, Tennis Elbow, Skin Graft, Aging, Osteo Arthritis Knee가 있다.
[0041]
[0042] 1. Method for extracting or concentrating regeneration factor-rich plasma (RRP)
[0043] In one embodiment of the present invention, a method for extracting or concentrating regeneration factor-rich plasma (RRP) from blood using aqueous solution fractionation is provided.
[0044]
[0045] In the present invention, the term "aqueous two-phase system (ATPS)" refers to a system that is formed of two immiscible aqueous solutions, can separate the liquid-liquid phase, and can effectively extract, separate, purify, and concentrate proteins, membranes, viruses, enzymes, nucleic acids, and other biomolecules. However, recent studies on aqueous two-phase system have shown relatively promising results with high yields, but in some cases, only modest purification factors were obtained due to the nonspecific separation mechanism used by the aqueous two-phase system process.
[0046] All of the key processing parameters involved in aqueous binary fractionation are related to influencing the partitioning behavior of the process stream components. For example, whether a molecule partitions into the top or bottom phase is determined by the properties of the molecule (e.g., charge, MW, and solvation) and the properties of the polymer (e.g., concentration, MW, and hydrophobicity). Furthermore, the physicochemical environment of the system (e.g., temperature, pH, and ionic strength) also influences the yield and purification factor of the concentration and extraction processes by aqueous binary fractionation. Ensuring optimal performance requires a careful balance of various interplay factors and the necessary balance between different operating parameters. Furthermore, aqueous binary fractionation often struggles to obtain high yields of only the desired target compounds due to a lack of fundamental knowledge about the partitioning of biological components. Therefore, process optimization requires a design of experiments approach based on fundamental knowledge of biological components, along with extensive screening of conditions. Consequently, the extensive process development of new aqueous binary fractionation methods is a time-consuming and labor-intensive endeavor.
[0047] Despite these limitations, the aqueous solution fractionation method of the present invention concentrates and extracts particles by creating two aqueous solution phases, and thus, by using the aqueous solution fractionation method, only regeneration factor-rich plasma (RRP) can be concentrated and extracted from blood with a high yield.
[0048]
[0049] In the present invention, "regeneration factor" refers to a protein, also called a growth factor, that is involved in cell growth, proliferation, and differentiation. Depending on the type, these regeneration factors bind to specific receptors to exhibit their respective functions and act as cellular signaling molecules. By using these regeneration factors as delivery vehicles in conjunction with biomaterials in tissue engineering, cell growth and differentiation can be promoted, resulting in effective tissue regeneration. Furthermore, the introduction of appropriate biomaterials for tissue regeneration and an appropriate drug delivery system for growth factors, which are essential factors for cell growth and differentiation, is crucial. However, these regeneration factors face significant challenges in isolation and purification. These regeneration-related proteins influence the three stages of wound healing: the inflammatory phase, the trophic phase, and remodeling. However, these growth factors have weaknesses such as a short biological half-life, a lack of sustained stability, and selective tissue compatibility.
[0050]
[0051] The above regenerative factors or growth factors include, but are not limited to, various types of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), etc. Among the above regenerative factors, important regenerative factors include epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), and it is particularly important that platelet-derived growth factor (PDGF) is abundantly contained in regenerative factor-rich plasma (RRP).
[0052] More specifically, the wound or wound healing process is achieved through epithelialization, wound contraction, collagen synthesis, and granulation tissue production. In full-thickness wounds, wound contraction plays a primary role, whereas in partial-thickness wounds with remaining skin appendages, healing through epithelialization is more important than contraction. During wound healing, several factors are known to induce wound healing cells to migrate to the wound, divide, and proliferate. These factors include chemoattractants (attachment factors) and growth promoting factors.
[0053] Among the various growth factors known to date, the most effective and clinically applicable for wound healing are epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). Since its first discovery in 1961, EGF has been known to act as a strong mitogen for epidermal cells and significantly affect epithelialization through culture and animal experiments. PDGF, discovered in 1985, is known to promote collagen deposition and granulation tissue formation at the wound site by causing chemotatic and mitogenic activities on fibroblasts. It is known to have a greater effect on the proliferation and contraction phase of wound healing than on the epithelialization phase of the wound.
[0054]
[0055] In the present invention, the above “epidermal growth factor (EGF)” refers to a protein that binds to the receptor EGFR and stimulates cell growth and differentiation. Human EGF is 6 kDa, has 53 amino acid residues, and 3 intramolecular disulfide bonds. In addition, among regenerative factors, epidermal growth factor is known to play a key role in skin regeneration and anti-aging, and is therefore being used as a functional cosmetic ingredient. In addition, epidermal growth factor is not only currently listed in the International Cosmetic Ingredient Dictionary (ICID) of the Cosmetic Products Association (CTFA) in the United States, but has also been approved as a cosmetic raw material by the Korea Food and Drug Administration (MDFS), allowing it to be used as an official cosmetic raw material both domestically and internationally (KFDA Notice No. 2006-12, April 12, 2006).
[0056] In the present invention, the "platelet-derived growth factor (PDGF)" is one of numerous growth factors that regulate cell growth and division. In particular, PDGF plays a crucial role in angiogenesis, blood vessel growth from pre-existing vascular tissue, and mitosis, i.e., proliferation, of mesenchymal cells such as fibroblasts, osteoblasts, tenocytes, vascular smooth muscle cells, and mesenchymal stem cells. As a result, PDGF is used in medicine to help treat chronic ulcers and as an alternative to bone autografts to stimulate bone regeneration and repair in orthopedic surgery and periodontal treatment. Furthermore, PDGF is a protein required for cell division of fibroblasts, a type of connective tissue cell during wound healing. Specifically, PDGF administered to monocyte-macrophages and fibroblasts is known to stimulate chemotaxis, proliferation, and gene expression, significantly increasing the influx of inflammatory cells and fibroblasts, thereby accelerating the formation of extracellular matrix and collagen, thereby shortening the healing process.
[0057]
[0058] In the present invention, the “Regeneration factor-rich plasma (RRP)” refers to plasma in which proteins related to regeneration existing in the blood are concentrated, and does not include platelets or exosomes. However, depending on the purpose of use, RRP may include platelets or exosomes containing regeneration factors among platelets or exosomes. The RRP extracted and concentrated by the method of the present invention is a blood concentrate and contains 3-5 times more RRP than whole blood. RRP promotes regeneration or enables proliferative therapy through the aforementioned roles related to regeneration at a concentration higher than the physiological level. Regeneration factor-rich plasma (RRP) can help treat and regenerate various tissues such as bone, cartilage, tendon, ligament, and muscle, as well as in the field of maxillofacial and plastic surgery.
[0059]
[0060] 2. Skin beauty method, cosmetic product, cosmetic composition using extracted or concentrated RRP (Regeneration factor-rich plasma)
[0061] In another embodiment of the present invention, a skin care method, a skin care cosmetic, and a skin care composition comprising RRP (Regeneration factor-rich Plasma) extracted or concentrated by a method according to any one of claims 1 to 12 are provided.
[0062]
[0063] In the present invention, a method is provided for producing regeneration factor-rich plasma (RRP) containing at least five times more regeneration factors and proteins than whole blood by an aqueous solution dichotomization method, and further, selecting concentrated regeneration factor proteins such as bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), etc., by a chromatographic method and applying the same to cosmetics and treatment.
[0064] In a preferred embodiment of the present invention, the skin beauty composition or cosmetic composition is preferably, but is not limited to, a cosmetic for preventing skin aging. In the present invention, anti-aging may refer to preventing, delaying, and / or improving aging phenomena caused by internal factors including genetic factors and external factors including ultraviolet rays. For example, in the present invention, anti-aging refers to an effect known in the art that can slow down, prevent, or prevent the aging process, and may inhibit aging of the body or enhance vitality of the body. Specifically, in the present invention, anti-aging may refer to inhibiting aging of cells in relation to cell metabolism, division, or immune function.
[0065] In particular, the anti-aging cosmetic composition provided by the present invention contains a large amount of regeneration factor-rich plasma, and thus can prevent, delay and / or improve skin aging caused by internal factors including genetic factors and external factors including ultraviolet rays.
[0066] In the present invention, the cosmetic composition can be manufactured in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a hair loss agent {for cosmetic use}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a beauty soap, a shampoo, a hand cleanser (hand cleaner), a medicated soap {for non-medical use}, a cream soap, a facial wash, a body cleanser, a scalp cleanser, a hair rinse, a cosmetic soap, a tooth whitening gel, a toothpaste, etc. To this end, the composition of the present invention may further include a solvent, appropriate carrier, excipient, or diluent commonly used in the manufacture of cosmetic compositions.
[0067] The type of solvent that can be further added to the cosmetic composition of the present invention is not particularly limited, but for example, water, saline solution, DMSO, or a combination thereof can be used, and carriers, excipients, or diluents include, but are not limited to, purified water, oil, wax, fatty acid, fatty acid alcohol, fatty acid ester, surfactant, humectant, thickener, antioxidant, viscosity stabilizer, chelating agent, buffer, lower alcohol, etc. In addition, whitening agents, moisturizers, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, and antifungal agents can be included as needed.
[0068] As the above oils, hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil, and avocado oil can be used, and as the waxes, beeswax, spermaceti, carnauba, candelilla, montan, ceresin, liquid paraffin, and lanolin can be used.
[0069] As fatty acids, stearic acid, linoleic acid, linolenic acid, and oleic acid can be used; as fatty acid alcohols, cetyl alcohol, octyl dodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol, and hexadecanol can be used; and as fatty acid esters, isopropyl myristate, isopropyl palmitate, and butyl stearate can be used. As surfactants, cationic surfactants, anionic surfactants, and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferable if possible.
[0070] In addition, it may include absorbents, thickeners, antioxidants, etc., which are widely known in the cosmetics field, and the types and amounts of these are as known in the art.
[0071]
[0072] 3. Composition for wound treatment and regeneration using extracted or concentrated RRP (Regeneration factor-rich plasma)
[0073] In another embodiment of the present invention, a wound treatment composition and a regenerative composition comprising extracted or concentrated RRP (Regeneration factor-rich Plasma) are provided.
[0074]
[0075] In the present invention, the “wound” is preferably selected from the group consisting of wounds, bedsores, burns, abrasions, puncture ulcer wounds, stab wounds, chronic skin wounds caused by active oxygen, bruises, cuts, wounds of the mucous membrane of the throat or mouth, lacerations, diabetic ulcers, leg ulcers, hypertensive ischemic ulcers, venous ulcers, and foot ulcers, but is not limited thereto.
[0076] In addition, the pharmaceutical composition of the present invention may further include an appropriate carrier, excipient, or diluent according to a conventional method. Carriers, excipients, and diluents that may be included in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0077] In addition, the pharmaceutical composition according to the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions, each according to a conventional method.
[0078] In detail, when formulating, it can be prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants that are commonly used.
[0079] Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations can be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.
[0080] Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives.
[0081] Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
[0082] Non-aqueous solvents and suspending agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, Tween 61, cocoa butter, laurin butter, and glycerogelatin.
[0083] Routes of administration of the pharmaceutical composition according to the present invention include, but are not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Oral or parenteral administration is preferred.
[0084] The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. The pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
[0085] The pharmaceutical composition of the present invention may vary depending on various factors including the activity of the specific compound used, age, body weight, general health, sex, diet, administration time, administration route, excretion rate, drug combination, and severity of the specific disease to be prevented or treated, and the dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route, and period, but may be appropriately selected by those skilled in the art, and may be administered at 0.0001 to 50 mg / kg or 0.001 to 50 mg / kg per day. Administration may be administered once a day or divided into several times. The dosage does not limit the scope of the present invention in any way. The pharmaceutical composition according to the present invention may be formulated as a pill, a dragee, a capsule, a liquid, a gel, a syrup, a slurry, or a suspension.
[0086]
[0087] 4. RRP or vessel used to extract or concentrate RRP and platelets
[0088] In one embodiment of the present invention, a container for extracting or concentrating RRP according to the method is provided, comprising: a body (100) that provides an internal space for receiving blood and extracting or concentrating RRP during centrifugation; a first lid (200) provided on one side of the body (100) to inject the blood or a separate substance into the internal space of the body; and a second lid (300) provided on the other side of the body (100) opposite to the one side to discharge the RRP extracted or concentrated from the body (100).
[0089]
[0090] In the present invention, the “container” is not particularly limited as long as it is a container generally used for centrifugation or aqueous solution fractionation, and may preferably be a medical container. In addition, although one embodiment of the invention discloses a container for extracting or concentrating RRP, this is only one embodiment, and not only RRP but also RRP and platelets can be extracted or concentrated at the same time. In addition, it can also be used as a syringe adapter for extracting and concentrating not only RRP but also RRP and platelets and applying them to the skin, etc. That is, it is configured with a structure in which the body (100) converges toward the bottom, and when combined with a syringe, it can be sealed, and a hole of an appropriate size can be present at the bottom so that it is easy to apply to the skin, etc. As the medical container, for example, there may be mentioned a syringe used for a syringe barrel (hereinafter, “syringe”) and a syringe filled with a drug solution or medicine (hereinafter, also referred to as a prefilled syringe), a storage container used for a storage container filled with a drug solution or medicine (hereinafter, also referred to as a drug solution storage container), etc. Here, a prefilled syringe is a syringe-shaped preparation in which a drug solution or medicine is pre-filled, and there is a single-chamber type filled with one type of liquid and a double-chamber type filled with two types of medicine. Most prefilled syringes are single-chamber types, but for double-chamber types, there are liquid / powder type preparations composed of powder and its solution and liquid type preparations composed of two types of liquid. Examples of syringes and prefilled syringes include prefillable syringes, prefilled syringes for vaccines, prefilled syringes for anticancer drugs, and needleless syringes. Examples of drug storage containers include wide-mouth bottles, narrow-mouth bottles, medicine bottles, vial bottles, infusion bottles, bulk containers, petri dishes, test tubes, and analysis cells.More specifically, the examples include liquid, powder or solid pharmaceutical containers such as ampoules, press-through packages, intravenous fluid bags, drop containers and eye drop containers; sample containers such as test tubes for blood testing, blood collection tubes and specimen containers; analysis containers such as ultraviolet test cells; sterilization containers for medical devices such as scalpels, forceps, gauze and contact lenses; medical instruments such as disposable syringes and prefilled syringes; experimental devices such as beakers, vials, ampoules and test tube flasks; and housings for artificial organs.
[0091] In the present invention, the "body (100)" is intended to receive blood and provide an internal space in which the RRP is extracted or concentrated during centrifugation. It is not particularly limited as long as it can be used for centrifugation or aqueous solution fractionation. Furthermore, it is preferably intended to provide an internal space in which the RRP is extracted or concentrated, but is not particularly limited as long as it provides an internal space in which various biological substances other than the RRP are extracted or concentrated.
[0092] In the present invention, the "first lid (200)" is not particularly limited as long as it can seal the container during the RRP or RRP and platelet extraction and concentration process through centrifugation or aqueous solution fractionation. Preferably, it is elastic and can seal the container, and may be formed of a rubber stopper or the like.
[0093] In another embodiment of the present invention, the first lead (200) provides a container for extracting or concentrating RRP, which is provided on a cover (120) provided on the upper side of the body (100) to open and close the body.
[0094] In addition, the above “first lead (200)” can be opened and closed and can be separated vertically, and a part of the first lead can be fixed to a fixing member (122). In this way, by being fixed to the fixing member (122) during the opening and closing process, it can be easily opened or closed, and by fixing one side of the first lead to the fixing member, the movement of the first lead can be restricted during the opening and closing process, thereby preventing the first lead from being separated and lost. In addition, the first lead (200) can be configured to have a size suitable for fitting the main body of the syringe. Preferably, it is made of an elastic material, such as rubber, which can seal when the main body of the syringe is fitted.
[0095] In the present invention, the "second lid (300)" can be opened and closed and configured to be of a size suitable for inserting the main body of the syringe. Preferably, it is made of an elastic material, such as rubber, that can seal when the main body of the syringe is inserted. In this way, the container used for extracting or concentrating RRP according to the above method has a first lid (200) and a second lid (300) at the top and bottom, so that the syringe can be inserted at the top or bottom, and thus has the advantage of being able to extract any of the materials separated from the top and bottom first. In addition, in this case, when extracting a material through the syringe, by opening the opposite lid, the pressure inside the device is maintained constant, which has the advantage of allowing the material to be easily withdrawn using the syringe. In addition, conversely, when only one of the two lids is opened, there is the advantage of preventing the liquid inside from flowing out due to the pressure balance between the internal pressure of the body (100) and the external atmospheric pressure. Specifically, when the container is used, if the upper lid is closed, the liquid inside the body does not flow out even if the lower lid is opened.
[0096]
[0097] In another embodiment of the present invention, a container for extracting or concentrating RRP is provided, wherein the other side of the body (100) is formed to narrow toward the second lead (300). In this way, since the other side of the body (100) is formed to narrow toward the second lead (300), there is an advantage in that even a small amount of biological material can be extracted with a syringe through the lower portion, and when used as a syringe adapter for application to the skin or the like, even a small amount of biological material can be accurately applied. In addition, for this purpose, a scale may be marked on the body (100) to indicate the capacity.
[0098] In another embodiment of the present invention, a container for extracting or concentrating RRP is provided, which further includes a support (140) that wraps the other outer surface of the body (100) around the second lid (300). As described above, the other end of the body (100) is formed to narrow toward the second lid (300), which may result in a disadvantage in that it is not sturdy during centrifugation and may break or have to be stored lying down. However, by further including the support (140), the body (100) is supported firmly during centrifugation, and the container can be stored upright, thereby improving the ease of storage.
[0099] In addition, a mounting groove (144) may be provided on the outer surface of the support (140) so that a container for extracting or concentrating the RRP according to the present invention can be stably mounted on a device that performs centrifugation.
[0100]
[0101] For the extraction of plasma regeneration material.
[0102] 1. Open the rubber stopper on the top and inject 20 ml of blood into the main body.
[0103] 2. Close the rubber stopper and centrifuge.
[0104] 3. Open the rubber stopper at the bottom and insert a 20ml syringe into the main body. Open the upper rubber stopper and pull the syringe to withdraw the red blood cells and platelets.
[0105] 4. Close the lower rubber stopper, open the upper rubber stopper, inject the polymer, and mix.
[0106] 5. Close the upper rubber stopper and proceed with centrifugation.
[0107] 6. The separated regenerative material at the bottom can be used in the same order as step 3 by taking it out with a syringe.
[0108]
[0109] In order to extract platelets and regenerative materials together,
[0110] 1. Open the rubber stopper on the top and inject 20 ml of blood into the main body.
[0111] 2. Put the polymer into the main body.
[0112] 3. Close the rubber stopper and centrifuge.
[0113] 4. Open the rubber stopper at the bottom and insert a 20ml syringe into the body. Open the upper rubber stopper and pull the syringe to remove the red blood cells.
[0114] 5. A 5ml syringe can be inserted into the bottom and used in the order of extracting the platelet and regenerative material layers.
[0115]
[0116] To use as a syringe adapter for application,
[0117] 1. Prepare a sample using the above method of extracting plasma regenerated material and extracting platelets and regenerated material together, and prepare a new, unused device.
[0118] 2. Open the upper rubber stopper and inject the sample into the main body.
[0119] 3. To accurately dispense the injected sample onto the skin, attach a 20ml syringe filled with air to the top and open the support and rubber stopper.
[0120] 4. It can be used in the order of pressing the syringe inserted at the top and applying the drug in the main body through the lower part of the main body.
[0121]
[0122] The present invention enables the concentration and extraction of regeneration factor-rich plasma (RRP) from blood with a high yield, and the regeneration factors in RRP, such as bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF), can be extracted and purified with high efficiency to produce the same.
[0123]
[0124] FIG. 1 is a perspective view illustrating one embodiment of a container for extracting or concentrating regeneration factor-rich plasma (RRP) according to the present invention.
[0125] FIG. 2 is a cross-sectional view illustrating one embodiment of a container for extracting or concentrating RRP according to the present invention illustrated in FIG. 1.
[0126] Figure 3 is a result confirming that nanoparticles were removed when the RRP extraction or concentration method according to the present invention was followed.
[0127] Figure 4 is an ELISA result confirming that EGF was concentrated up to about 8.7 times compared to before concentration when using the RRP extraction or concentration method according to the present invention.
[0128] Figure 5 is an ELISA result confirming that PDGF was concentrated up to about 10.518 times compared to before concentration when using the RRP extraction or concentration method according to the present invention.
[0129] Figure 6 is an MTT analysis result showing that the RRP provided by the present invention has an antioxidant effect on human skin cells.
[0130]
[0131] [Explanation of symbols]
[0132] 100: Body
[0133] 120: Cover
[0134] 122: Fixed member
[0135] 140: Support
[0136] 144: Mounting groove
[0137] 200: 1st lead
[0138] 300: Second Lead
[0139]
[0140] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.
[0141]
[0142] Example
[0143] [Preparation Example] Removal of exosomes
[0144] As a specific example, bovine blood was used. Purchased bovine blood was completely thawed at room temperature and dispensed into a 50 ml conical tube. The bovine blood was centrifuged at 200 g force for 10 minutes, and the supernatant was extracted using a pipette. The extracted supernatant was centrifuged at 3,000 g force for 30 minutes, and the supernatant was extracted again. The extracted supernatant was centrifuged again at 100,000 g force for 2 hours, and the supernatant was extracted. The extracted supernatant was centrifuged again at 100,000 g force for 2 hours, and the supernatant was extracted. As a result of analysis using nano-tracking analysis, it was confirmed that nanoparticles larger than 30 nm in size, including 92.3%±14 exosomes, were removed, as shown in Figure 3.
[0145]
[0146] [Example 1] Formation of an aqueous ideal system
[0147] Salt and polymer were added to the sample from which exosomes had been removed to obtain the concentrations shown in Table 1. The sample was mixed by vortexing and incubated at room temperature for 30 minutes. The sample kept at room temperature was centrifuged at 1000 g force for 30 minutes, and the RRP concentrated in the lower layer was extracted. At this time, systems A, B, and C in Table 1 formed an aqueous two-phase system, but systems D and E did not form an aqueous two-phase system.
[0148] Sodium sulfate (%) PEG (%) Hyaluronic acid (%) System A4.3163 System B2.8145 System C7123.5 System D2.555 System E1312
[0149]
[0150] [Example 2] Concentration of regeneration factor-rich plasma (RRP)
[0151] Regeneration factor-rich plasma (RRP) was concentrated through the aqueous two-phase system formed in Example 1. EGF ELISA KIT and PDGF ELISA KIT were used to confirm the concentration of the concentrated RRP. As a result, as can be seen in FIGS. 4 and 5, although system B concentrated EGF about 8.7 times and PDGF about 10.518 times compared to before concentration, showing the most efficient concentration, system A, which formed an aqueous two-phase system, concentrated EGF about 5 times and PDGF about 8 times compared to before concentration, and system C also concentrated EGF about 3 times and PDGF about 3 times compared to before concentration. Therefore, it was confirmed that the aqueous two-phase system provided by the present invention can efficiently concentrate regeneration factor-rich plasma (RRP).
[0152]
[0153] [Example 3] Confirmation of the antioxidant effect of concentrated regeneration factor-rich plasma (RRP).
[0154] To confirm the antioxidant effect of the regeneration factor-rich plasma (RRP) concentrated in Example 2 on human skin cells, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed. Briefly, HaCaT 5 × 10 4Cells were cultured in 96-well plates at a density of 10 cells / mL for 24 h. Afterwards, RRP was treated with 1 mM H2O2 at final concentrations of 0.1%, 1%, and 5% for 8 h. Saline was used as a control. After RRP treatment, the medium was removed, and 4 μL of 5 mg / mL MTT reagent was added and cultured for 4 h. After removing the medium, 100 μL of DMSO was added and dissolved for 10 min. Cell viability was determined by measuring the absorbance at a wavelength of 570 nm.
[0155] As a result, as shown in Fig. 6, it was found that the RRP concentrated by Example 2 increased the survival rate by at least 2 times and at most 3 times compared to damaged cells at all concentrations, including 0.1%, 1%, and 5%. Accordingly, it was confirmed that the regeneration factor-rich plasma (RRP) concentrated by the aqueous solution fractionation method provided in the present invention is rich in regeneration factors, promotes cell proliferation, and is effective in regenerative treatment, and also has an antioxidant effect on human skin cells, so it is useful for skin beauty.
[0156]
[0157] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description of the present specification below.
Claims
1. A method for extracting or concentrating regeneration factor-rich plasma (RRP) from blood using aqueous solution fractionation.
2. In paragraph 1, A method for extracting or concentrating RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
3. In paragraph 2, A method for extracting or concentrating RRP, wherein the aqueous solution fractionation is formed by adding at least one additive selected from the group consisting of sodium sulfate, polyethylene glycol (PEG), and hyaluronic acid.
4. In paragraph 3, A method for extracting or concentrating RRP, wherein the sodium sulfate is 1 to 10% (w / w).
5. In paragraph 3, A method for extracting or concentrating RRP, wherein the polyethylene glycol (PEG) is 5 to 20% (w / w).
6. In paragraph 3, A method for extracting or concentrating RRP, wherein the hyaluronic acid is 1 to 10% (w / w).
7. In paragraph 6, A method for extracting or concentrating RRP, wherein the average molecular weight of the hyaluronic acid is 100,000 or more and 500,000 or less.
8. In paragraph 7, A method for extracting or concentrating RRP, wherein the blood is plasma.
9. In paragraph 8, A method for extracting or concentrating RRP, wherein the plasma is free of platelets or exosomes.
10. In paragraph 9, A method for extracting or concentrating RRP, wherein the above platelets or exosomes are removed through centrifugation or chromatography.
11. In paragraph 10, A method for extracting or concentrating RRP, further comprising a step of purifying impurities.
12. In paragraph 11, A method for extracting or concentrating RRP, wherein the step of purifying the above impurities is performed by using a chromatography filter fixed with Apo A antibody and Apo B antibody.
13. In paragraph 12, A method for extracting or concentrating RRP, wherein the above extraction method selects RRP using a chromatography filter on which an anti-RRP antibody is immobilized.
14. A skin cosmetic method comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 13.
15. In paragraph 14, A skin cosmetic method comprising RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
16. A cosmetic product for skin care containing RRP (Regeneration factor-rich Plasma) extracted or concentrated by a method according to any one of claims 1 to 13.
17. In paragraph 16, A cosmetic product for skin care comprising RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
18. A skin cosmetic composition comprising RRP (Regeneration factor-rich Plasma) extracted or concentrated by a method according to any one of claims 1 to 13.
19. In paragraph 18, A skin cosmetic composition comprising RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
20. A composition for wound treatment comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 13.
21. In paragraph 20, A wound healing composition comprising RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
22. In paragraph 21, A composition for treating a wound, wherein the above wound is selected from the group consisting of wounds, bedsores, burns, abrasions, puncture ulcer wounds, stab wounds, chronic skin wounds caused by active oxygen, bruises, cuts, wounds of the mucous membrane of the throat or mouth, lacerations, diabetic ulcers, leg ulcers, hypertensive ischemic ulcers, venous ulcers, and foot ulcers.
23. A regenerative composition comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 13.
24. In paragraph 23, A regenerative composition comprising RRP, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
25. In paragraph 24, The above regeneration is selected from the group consisting of craniomandibular disorder, gastric ulcer by endoscopic submucosal dissection, human autologous fat grafting, treatment of knee osteoarthritis, treatment of chronic non-healing ulcer, hair regeneration therapy for androgenetic alopecia, treatment of Achilles tendon rupture, high-risk proliferative diabetic retinopathy, high-risk proliferative diabetic retinopathy, knee OA, patellar dislocation, lumbar facet joint syndrome, retinitis pigmentosa, diabetic macular edema, traumatic bone cyst, high-risk proliferative diabetic retinopathy, scar, dry eye, Sjogren's syndrome, osteoarthritis, meniscus lesion, freckles, muscle damage, elbow ulnar neuropathy, chronic ulcer, alopecia, epicondylitis, bone resorption, rotator cuff tear, thin endometrium, striae gravidarum, plantar fasciitis, hip dysplasia, osteoarthritis, muscle rupture, tennis elbow, skin graft, aging, knee arthritis, burns, renal failure, and atopic disease. A composition for regeneration, in which regeneration is required.
26. A container used to extract or concentrate regeneration factor-rich plasma (RRP) according to any one of paragraphs 1 to 13, A body that receives the blood and provides an internal space in which the RRP is extracted or concentrated during centrifugation; A first lead provided on one side of the body to inject the blood or a separate substance into the internal space of the body; and Including a second lead provided on the other side of the body opposite to the one side, so as to discharge the RRP extracted or concentrated from the body. A vessel for extracting or concentrating RRP.
27. In paragraph 26, The regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), brain-derived neutrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
28. In paragraph 27, The above first lead is provided on a cover provided on the upper side of the body to open and close the body. A vessel for extracting or concentrating RRP.
29. In paragraph 28, The other side of the above body is formed to narrow toward the second lead, A vessel for extracting or concentrating RRP.
30. In paragraph 29, Further comprising a support body that wraps the other outer surface of the body around the second lead; A vessel for extracting or concentrating RRP.
31. A wound treatment method comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 13.
32. A skin regeneration method comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 32.
33. An anti-aging cosmetic composition comprising regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 32.
34. In paragraph 33, An anti-aging cosmetic composition, wherein the regenerative factor is at least one regenerative factor selected from the group consisting of bone morphogenetic protein (BMP), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulinlike growth factor (IGF), transforming growth factor (TGF), brain-derived neurotrophic factor (BDNF), platelet derived growth factor (PDGF), placental growth factor (PlGF), and hepatocyte growth factor (HGF).
35. An anti-aging treatment method comprising administering to a subject regeneration factor-rich plasma (RRP) extracted or concentrated by a method according to any one of claims 1 to 13.
Citation Information
Patent Citations
Method for isolation of bacteriorhodopsin by aqueous two phase interfacial condensation
KR1019990086127A
Composition for skin regeneration by using medium or secretion of embryonic stem cell derived endothelial progenitor cells and use thereof
KR1020100098298A
a extraction method of bio-friendly collagen using egg shell membrane
KR1020220114110A
